Two studies of the use of Avastin in ovarian cancer showed that the drug slowed tumor growth but did not improve overall survival.
“While we are looking for that silver bullet, this is a gift that shouldn’t be overlooked,” said Karen Orloff Kaplan, chief executive of the Ovarian Cancer National Alliance.
In one study, the use of Avastin provided an additional six weeks of progression free survival; in another study the drug provided an additional 16 weeks of progression free survival. There is currently no biomarker or other test to determine which patients will benefit from Avastin, and the side effects of the drug can be serious. Because the Food and Drug Administration has been focusing on overall survival benefits, many do not think the drug will be approved for ovarian cancer in the United States.
Read more here